Order and treatment record
Bring or send the signed order, diagnosis, intended dose, last injection or oral dose, next due date, initiation history, and prescriber contact details.
Perseris availability and psychiatry coordination in NYC
Indivior discontinued US availability of Perseris effective May 31, 2026. The manufacturer says this action was not taken because of safety or effectiveness concerns.
Perseris was a monthly risperidone injection approved for adults with schizophrenia. Indivior discontinued U.S. availability effective May 31, 2026, so Nao Medical does not present Perseris as a currently bookable injection. A psychiatry visit can review records, discuss continuity, and coordinate with the responsible prescriber on currently available options. Do not delay a scheduled dose without contacting the prescriber.
Records first, appointment second
A complete handoff helps prevent an incorrect dose, an avoidable delay, or a visit at the wrong clinic.
Perseris availability ended
Indivior ended US availability of Perseris on May 31, 2026. The manufacturer says the decision was not due to safety or effectiveness issues. Contact the responsible prescriber before the next due date to discuss continuity and an alternative plan. Some supplier inventory may remain briefly. Ask the pharmacy and treating clinic directly whether your prescribed dose can be supplied. Even if stock is found, ask about the longer-term treatment plan rather than assuming future monthly access will continue.
Perseris availability and transition
Indivior discontinued US availability of Perseris effective May 31, 2026. The manufacturer says this action was not taken because of safety or effectiveness concerns. If you have been receiving Perseris, the useful next step is a continuity plan with the responsible prescriber before the next dose is due. Discuss a continuity plan rather than assuming a new Perseris start can be supplied.
Eligibility: Perseris availability and transition
The last available label describes monthly treatment of schizophrenia in adults, with established oral risperidone tolerability first. The labelled transition uses specified oral doses and does not recommend a loading dose or routine oral supplementation. These details help interpret previous treatment records. They do not establish a new-start supply path.
What to expect: Perseris availability and transition
Confirm the last injection and next due date
Give your psychiatrist the Perseris strength, administration date, any oral medicines and the expected next appointment. Contact the team early if the pharmacy cannot fill the order.
Discuss an alternative before a gap develops
The clinician reviews previous response, side effects, diagnosis and practical needs before selecting an oral or injectable alternative. A medicine with the same ingredient is not automatically a direct replacement.
Document the change and follow-up
Obtain a written plan for when the new medicine begins, any oral coverage and the next review. Ask who will receive the administration record and whom to contact if symptoms or side effects change.
Preparing for your appointment
Bring previous Perseris administration records and pharmacy messages about availability. Include the exact strength and last date. Tell the team about restlessness, weight changes, sexual or menstrual effects, sedation and injection-site symptoms. Ask the prescriber to clarify the alternative regimen rather than seeking a product substitution from the administration site alone.
Risks and when to seek help
The boxed warning states that antipsychotics increase the risk of death in older adults with dementia-related psychosis. This medicine is not approved for that use. Perseris-labelled risks include movement disorders, sedation, weight and metabolic changes, dizziness and raised prolactin. The medicine already injected continues releasing over time. A switch must account for that continuing exposure. Do not stop other prescribed medicines, double a dose or substitute a different injection yourself. Seek emergency care for severe trouble breathing, throat or tongue swelling, loss of consciousness, or high fever with severe muscle stiffness and confusion. Contact the treating team promptly for new involuntary movements, severe restlessness, worsening psychosis, marked dizziness or troublesome injection-site symptoms. Do not wait for the next routine injection to report a serious concern.
Follow-up and treatment review
The manufacturer notes that some supplier inventory may remain for a few months after discontinuation. That is not a promise of a usable dose at a particular pharmacy. If a dose cannot be obtained, contact the prescriber promptly. Monitor symptoms during the transition and arrange the next psychiatric review rather than waiting for a relapse.
Appointments, costs and coverage
Ask the current pharmacy and prescriber to confirm whether a planned dose can actually be supplied. Even if remaining inventory is found, discuss the longer-term plan. The alternative medicine may need a new prescription, benefit review, authorization and delivery path. Confirm the alternative product’s actual supply and your benefits before booking.
Questions about your care
Can I book a new Perseris injection at Nao Medical? What should I do if I was receiving Perseris?
Indivior discontinued US availability of Perseris effective May 31, 2026. The manufacturer says this action was not taken because of safety or effectiveness concerns. If you have been receiving Perseris, the useful next step is a continuity plan with the responsible prescriber before the next dose is due. Discuss a continuity plan rather than assuming a new Perseris start can be supplied.
Give your psychiatrist the Perseris strength, administration date, any oral medicines and the expected next appointment. Contact the team early if the pharmacy cannot fill the order.
The clinician reviews previous response, side effects, diagnosis and practical needs before selecting an oral or injectable alternative. A medicine with the same ingredient is not automatically a direct replacement.
Obtain a written plan for when the new medicine begins, any oral coverage and the next review. Ask who will receive the administration record and whom to contact if symptoms or side effects change.
The manufacturer notes that some supplier inventory may remain for a few months after discontinuation. That is not a promise of a usable dose at a particular pharmacy. If a dose cannot be obtained, contact the prescriber promptly. Monitor symptoms during the transition and arrange the next psychiatric review rather than waiting for a relapse.
Can Nao switch me from Perseris to another injection?
A switch needs the responsible psychiatrist's documented plan, not just an administration appointment. Review the exact current product, strength, last dose, response and tolerability. The new injection has its own indication, prior-treatment, loading or oral-coverage rules. Ask whether Nao provides the prescribing evaluation or accepts an outside order, and confirm delivery, the administering site and follow-up before changing treatment. Do not stop or convert medicines yourself.
Did Perseris require oral overlap?
Historically, the Perseris label did not require a loading dose or routine oral risperidone supplementation after establishing oral tolerability. That historical regimen is not a current supply offer: the manufacturer discontinued US availability effective May 31, 2026. Ask the responsible psychiatrist for a continuity plan using the actual last dose and available alternatives instead of arranging a new Perseris start.
What if my symptoms are returning before I can see my prescriber?
Contact the responsible clinician promptly for returning symptoms or a medication gap. Do not add, stop or convert medicines yourself. Use emergency care for immediate danger, severe confusion, unsafe mania/psychosis or inability to care safely for yourself; an ordinary appointment is not an emergency pathway.
Does Perseris have an active FDA REMS?
The reviewed current US prescribing information for Perseris availability and transition does not specify a restricted REMS administration/distribution program. That does not remove the medicine’s prescribing, administration, initiation or monitoring requirements. Confirm the exact product and current FDA status with the treating clinician and dispensing service; a manufacturer access program is not itself an FDA REMS.
Is a lump after a Perseris injection expected, and what should I do?
The Perseris label says a lump may remain for several weeks and decrease in size over time. Do not rub or massage the site, and avoid pressure from belts or tight clothing. Contact the treating team for troublesome or worsening injection-site symptoms rather than assuming every lump is harmless. Severe allergic symptoms, such as trouble breathing or throat swelling, need emergency assessment.
Medical sources
- Perseris US prescribing information and patient labeling (DailyMed)
- Indivior: Information on availability for Perseris
- Uzedy US prescribing information and patient labeling (DailyMed)
- Risperdal Consta US prescribing information and patient labeling (DailyMed)
- NIMH: Mental Health Medications
- NIMH: Depression
- NIMH: Schizophrenia
- HHS: Creating an emergency plan for telebehavioral health
- Clozapine US prescribing information and patient labeling (DailyMed)
What to prepare before scheduling
Medication and safety record
Include current medicines, allergies, prior adverse effects, pregnancy or breastfeeding considerations, recent hospitalization records, and relevant laboratory or monitoring results.
Coverage and delivery details
Share insurance cards, the specialty pharmacy or distributor if known, prior authorization status, and the intended patient-specific delivery destination.
Timing confirmation
Wait for the care team to confirm order acceptance, medication arrival, the eligible clinic, trained staff, and appointment time before traveling.
Evaluation and coordination locations
Bronx
174th Street
932 E 174th St, Bronx, NY 10460
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods. The administration clinic will be confirmed separately by the care team.
Queens
Astoria
37-15 23rd Ave, Astoria, NY 11105
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Bronx
Bartow Mall
2063A Bartow Ave, Bronx, NY 10475
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. The administration clinic will be confirmed separately by the care team.
Brooklyn
Crown Heights
341 Eastern Pkwy, Brooklyn, NY 11216
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. The administration clinic will be confirmed separately by the care team.
Long Island
Hicksville
232 W Old Country Rd, Hicksville, NY 11801
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities. The administration clinic will be confirmed separately by the care team.
Queens
Jackson Heights
80-10 Northern Blvd, Jackson Heights, NY 11372
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Queens
Jamaica
90-18 Sutphin Blvd, Jamaica, NY 11435
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Queens
Long Island City
30-07 36th Ave, Astoria, NY 11106
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Long Island
Mineola
135 Mineola Blvd, Mineola, NY 11501
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities. The administration clinic will be confirmed separately by the care team.
Manhattan
StuyTown
259 1st Ave, New York, NY 10003
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods. The administration clinic will be confirmed separately by the care team.
Brooklyn
Williamsburg
308 Graham Ave, Brooklyn, NY 11211
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. The administration clinic will be confirmed separately by the care team.
- DailyMed: current Perseris prescribing information
- FDA: current active REMS database
- Indivior Perseris availability notice
- FDA MedWatch: report a suspected medication problem
Official sources checked August 12, 2026. The DailyMed label shown above has an effective date of 2025-01-28 and identifies prescribing-information revision 01/2025. Questions or corrections about this medical information can be sent to service@naomedical.com.